JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days

Osimertinib 160mg once po everyday

Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.

Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.